Granted Patent
B2
US 12,589,119 · App. 17/309,177 · Granted Mar 31, 2026
Treatment of cachexia using fibroblast cells and products thereof
Assignee:
FIBROBIOLOGICS, INC.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Disclosed are methods and compositions related to treatment, amelioration or prevention of cachexia or inflammation related to cachexia in a subject. As disclosed, cachexia or inflammation related to cachexia can be treated, ameliorated or prevented by the administration of an effective amount of a composition including immune-modulating fibroblasts to the subject.
Claims (12)
1 . A method for ameliorating cachexia, or inflammation related thereto, in an individual, comprising administering an effective amount of immune-modulating fibroblasts to the individual; wherein the fibroblasts express detectable levels of one or more markers selected from the group consisting of SSEA3, SSEA4, Tra-1-60, Tra-1-81, Tra-2-54, Oct-4, CD13, CD44, CD49b, CD105, aminopeptidase N, and a combination thereof; and administered in the form of a single cell suspension.
2 . The method of claim 1 , wherein said cachexia, or inflammation related thereto, is initiated by a chronic inflammatory condition.
3 . The method of claim 1 , wherein said cachexia, or inflammation related thereto, is initiated by a condition selected from the group consisting of chronic infection, tuberculosis, human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS), cancer, coeliac disease, chronic obstructive pulmonary disease, multiple sclerosis, rheumatoid arthritis, congestive heart failure, familial amyloid polyneuropathy, mercury poisoning (acrodynia), Crohn's disease, untreated/severe type 1 diabetes mellitus, anorexia nervosa, hormonal deficiency, and a combination thereof.
4 . The method of claim 2 , wherein said chronic inflammatory condition is associated with the elevation of one or more detectable markers.
5 . The method of claim 4 , wherein said detectable markers are selected from the group consisting of C-reactive protein, Interleukin-1, Interleukin-6, TNF-alpha, and a combination thereof.
6 . The method of claim 1 , wherein said fibroblasts are derived from cells isolated from amniotic fluid.
7 . The method of claim 6 , wherein said amniotic fluid is selected from the species from the group consisting of humans, primates, dogs, cats, goats, elephants, cattle, horses, pigs, mice, rabbits, and a combination thereof.
8 . The method of claim 1 , wherein said fibroblasts do not express detectable levels of SSEA1.
9 . The method of claim 1 , wherein said fibroblasts are administered to the individual affected by cachexia, or inflammation related thereto, by one or more routes selected from the group consisting of epidural, intracerebral, intracerebroventricular, epicutaneous, sublingual, buccal extra-amniotic, nasal, intraarterial, intracardiac, intracavernous, intradermal, intralesional, intramuscular, intraocular, intraosseous, intraperitoneal, intrathecal, intrauterine, intravaginal, intravenous, intravesical, intravitreal, subcutaneous, transdermal, perivascular, transmucosal, and a combination thereof.
10 . A method of increasing the weight of an individual with cachexia or at risk of having cachexia, comprising the step of administering an effective amount of fibroblasts to the individual; wherein the fibroblasts express detectable levels of one or more markers selected from the group consisting of SSEA3, SSEA4, Tra-1-60, Tra-1-81, Tra-2-54, Oct-4, CD13, CD44, CD49b, CD105, aminopeptidase N, and a combination thereof;, and administered in the form of a single cell suspension.
11 . The method of claim 10 , wherein the individual is at risk for having cachexia has one or more conditions selected from the group consisting of tuberculosis, HIV/AIDS, cancer, coeliac disease, chronic obstructive pulmonary disease, multiple sclerosis, rheumatoid arthritis, congestive heart failure, familial amyloid polyneuropathy, mercury poisoning (acrodynia), Crohn's disease, untreated/severe type 1 diabetes mellitus, anorexia nervosa, and hormonal deficiency, or a combination thereof.
12 . The method of claim 10 , wherein the individual at risk for having cachexia has chronic infection.
Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Feb 25, 2026
From: FIGENE, LLC
To: SPINALCYTE LLC
Reel/Frame 073896/0367 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Feb 25, 2026
From: SPINALCYTE LLC
To: FIBROBIOLOGICS, INC.
Reel/Frame 074985/0732 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded May 4, 2021
From: O'HEERON, PETE; ICHIM, THOMAS
To: FIGENE, LLC
Reel/Frame 056120/0898 →
Continuity (2)
Provisional Application
62755542
· Nov 4, 2018
References Cited (161)
US 5188817A
· Ozick
· 1993
[cited by applicant]
US 7569385B2
· Haas
· 2009
[cited by examiner]
US 7850983B2
· Sevrain et al.
· 2010
[cited by applicant]
US 9173906B2
· Rolland et al.
· 2015
[cited by applicant]
US 9603878B2
· Berry et al.
· 2017
[cited by applicant]
US 20020037279A1
· Vandenburgh
· 2002
[cited by examiner]
US 20050170510A1
· Huang et al.
· 2005
[cited by applicant]
US 20090202500A1
· Tamai et al.
· 2009
[cited by applicant]
US 20140314726A1
· O'Heeron et al.
· 2014
[cited by applicant]
US 20170281685A1
· Bogin et al.
· 2017
[cited by applicant]
US 20180133258A1
· Ichim
· 2018
[cited by examiner]
US 20190101547A1
· Berger et al.
· 2019
[cited by applicant]
US 20190136299A1
· Putignani et al.
· 2019
[cited by applicant]
JP H06502406A
· 1994
[cited by applicant]
JP 2018511599A
· 2018
[cited by applicant]
WO WO1992006702A1
· 1992
[cited by applicant]
WO 2005017117A2
· 2005
[cited by applicant]
WO WO2007035843A2
· 2007
[cited by applicant]
WO WO2007149548A2
· 2007
[cited by applicant]
WO WO2010071862A1
· 2010
[cited by applicant]
WO WO2011015862A1
· 2011
[cited by applicant]
WO WO2012004566A1
· 2012
[cited by applicant]
WO WO2013070880A1
· 2013
[cited by applicant]
WO WO2014026012A2
· 2014
[cited by applicant]
WO WO2015035395A1
· 2015
[cited by applicant]
WO WO2016161290A1
· 2016
[cited by applicant]
WO WO2017023689A1
· 2017
[cited by applicant]
WO WO2018013612A1
· 2018
[cited by applicant]
WO WO2018015945A2
· 2018
[cited by applicant]
WO WO2018083700
· 2018
[cited by applicant]
WO WO2018132594
· 2018
[cited by applicant]
WO WO2018195308A1
· 2018
[cited by applicant]
WO WO2019094617A1
· 2019
[cited by applicant]
WO WO2019108756A1
· 2019
[cited by applicant]
WO WO2019191830A1
· 2019
[cited by applicant]
WO WO2019213518A1
· 2019
[cited by applicant]
WO WO2020093050A2
· 2020
[cited by applicant]
WO WO2020093051A1
· 2020
[cited by applicant]
WO WO2020144380A1
· 2020
[cited by applicant]
WO WO2020146874A1
· 2020
[cited by applicant]
WO WO2021050583A1
· 2021
[cited by applicant]
WO WO2021097423A1
· 2021
[cited by applicant]
WO WO2021134081A1
· 2021
[cited by applicant]
WO WO2021178395A1
· 2021
[cited by applicant]
WO WO2021211386A1
· 2021
[cited by applicant]
WO WO2021216460A1
· 2021
[cited by applicant]
WO WO2021232064A2
· 2021
[cited by applicant]
WO WO2022047486A2
· 2022
[cited by applicant]
Hematti P. Mesenchymal stromal cells and fibroblasts: a case of mistaken identity? Cytotherapy. May 2012;14(5):516-21. doi: 10.3109/14653249.2012.677822. Epub Mar. 29, 2012. PMID: 22458957. (Year: 2012).
[cited by examiner]
Hematti (Cytotherapy. May 2012;14(5):516-21. doi: 10.3109/14653249.2012.677822. Epub Mar. 29, 2012 (Year: 2012).
[cited by examiner]
Denu et al (Acta Haematol. 2016; 136(2): 85-97. doi: 10.1159/000445096.) (Year: 2016).
[cited by examiner]
Ichim et al. (J Transl Med (2018) 16:212 https://doi.org/10.1186/s12967-018-1536-1) (Year: 2018).
[cited by examiner]
Amitani et al., “Mechanism and Nutrition in Cachexia,” Jpn. J. Psychosom. Med., 56(10):1013-1022, 2016. (English abstract on p. 1022.).
[cited by applicant]
English Translation of Office Communication issued in Japanese Patent Application No. 2021-524163, dated Jul. 26, 2023.
[cited by applicant]
Carson et al., “Interleukin-6 as a Key Regulator of Muscle Mass during Chachexia”, Exercise and Sport Sciences Reviews, Oct. 2010, vol. 38, No. 4, pp. 168-176.
[cited by applicant]
Meazza et al., “Effect of Growth Hormone (GB) on the Immune System”, Pediatric Endocrinology Reviews, Aug. 2004, vol. 1, Suppl. 3, pp. 490-495.
[cited by applicant]
Denu et al., “Fibroblasts and Mesenchymal Stromal/Stem Cells are Phenotypically Indistinguishable,” Acta Haematologica, 136(2):85-97, 2016.
[cited by applicant]
Extended European Search Report issued in European Patent Application No. 19878537.0, dated Jun. 22, 2022.
[cited by applicant]
Ichim et al., “Fibroblasts as a practical alternative to mesenchymal stem cells,” Journal of Translational Medicine, 16(1), pp. 1-9, 2018.
[cited by applicant]
Jordana et al., “Immune-inflammatory functions of fibroblasts,” European Respiratory Journal, 7(12):2212-2222, 1994.
[cited by applicant]
American College of Surgeons “Best Practices Guidelines: The Management of Traumatic Brain Injury,” 2024, 99 pages.
[cited by applicant]
Anderson J.D., et al., “Mesenchymal Stem Cell-Based Therapy for Ischemic Stroke,” Chinese Neurosurgical Journal, Nov. 1, 2016, vol. 02, No. 01, 6 pages. doi: 10.1186/s41016-016-0053-4, Retrieved from the Internet: URL: …
[cited by applicant]
Arbelaez-Quintero I., et al., “To Use or Not to Use Metformin in Cerebral Ischemia: A Review of the Application of Metformin in Stroke Rodents,” Stroke Research and Treatment, 2017, vol. 2017, 13 pages.
[cited by applicant]
Balducci L., et al., “Chapter 30: The Differences Between Mesenchymal Stroma Cells and Fibroblasts,” in: Atkinson K., The Biology and Therapeutic Application of Mesenchymal Cells, John Wiley & Sons, Inc., 2017, pp. 441-…
[cited by applicant]
Balducci L., et al., “The Differences Between Mesenchymal Stromal Cells and Fibroblasts,” The Biology and Therapeutic Application of Mesenchymal Cells, K. Atkinson (ed.), John Wiley & Sons, Inc., 2017, pp. 441-455.
[cited by applicant]
Bhang Sh, et al., “Basic fibroblast growth factor promotes bone marrow stromal cell transplantation-mediated neural regeneration in traumatic brain injury,” Biochemical and Biophysical Research Communications, 2007, vol…
[cited by applicant]
Caplan H., et al., “Mesenchymal Stromal Cell Therapeutic Delivery: Translational Challenges to Clinical Application,” Frontiers in Immunology, 2019, vol. 10, art. 1645, 15 pages.
[cited by applicant]
Chen S.J., et al., “Brain-Derived Neurotrophic Factor-Transfected and Nontransfected 3T3 Fibroblasts Enhance Migratory Neuroblasts and Functional Restoration in Mice With Intracerebral Hemorrhage,” Journal of Neuropatho…
[cited by applicant]
Chou P.C., et al., “Intracerebral Transplantation of Erythropoietin-Producing Fibroblasts Facilitates Neurogenesis and Functional Recovery in an Ischemic Stroke Model,” Brain and Behavior, Feb. 28, 2019, vol. 09, 11 pag…
[cited by applicant]
Cohen S.P., et al., “A Double-Blind, Placebo-Controlled, Dose-Response Pilot Study Evaluating Intradiscal Etanercept in Patients with Chronic Discogenic Low Back Pain or Lumbosacral Radiculopathy,” Anesthesiology, Jul. …
[cited by applicant]
Cona L.A., “Stem Cell Therapy for TBI: Mechanisms and Effectiveness,” DVCSTEM, Apr. 9, 2025, 17 pages.
[cited by applicant]
Cosme et al. “Hypoxia-Induced Changes in the Fibroblast Secretome, Exosome, and Whole-Cell Proteome Using Cultured, Cardiac-Derived Cells Isolated from Neonatal Mice”, Journal of Proteome Research. Aug. 4, 2017, Epub Ju…
[cited by applicant]
Costa-Almeida R., et al., “Fibroblasts as Maestros Orchestrating Tissue Regeneration,” Journal of Tissue Engineering and Regenerative Medicine, Jan. 1, 2018, vol. 12, No. 01, doi: 10.1002/term.2405, pp. 240-251, Retriev…
[cited by applicant]
Cox CS, “Cellular therapy for traumatic neurological injury,” Pediatric Research, vol. 83, No. 1, pp. 325-332 (Jan. 2018).
[cited by applicant]
Cox C.S., et al., “Treatment of Sever Adult Traumatic Brain Injury using Bone Marrow Mononuclear Cells,” Stem Cells, Nov. 23, 2016, 28 pages.
[cited by applicant]
Cox J.R., et al., “Treatment of Severe Adult Traumatic Brain Injury Using Bone Marrow Mononuclear Cells,” Stem Cells, Nov. 1, 2016, vol. 35, pp. 1065-1079.
[cited by applicant]
Dekosky S.T., et al., “ Interleukm-1 Receptor Antagonist Suppresses Neurotrophin Response in Injured Rat Brain,” Annals of Neurology, Jan. 1996, vol. 39, No. 01, 02 Pages.
[cited by applicant]
Denu R.A., et al., “Fibroblasts and Mesenchymal Stromal/Stem Cells are Phenotypically Indistinguishable,” Acta Haematologhy, May 18, 2016, vol. 136, No. 02, pp. 85-97.
[cited by applicant]
English translation of Office Communication issued in Japanese Patent Application No. 2021-524164, dated Jul. 14, 2023. 16 pages.
[cited by applicant]
English translation of Office Communication issued in Japanese Patent Application No. 2021-525028, dated Sep. 5, 2023, 10 pages.
[cited by applicant]
Extended European Search Report issued in European Application No. 22896789.9, mailed on Sep. 25, 2025, 07 pages.
[cited by applicant]
Extended European Search Report issued in European Patent Application No. 19881814.8, dated Sep. 21, 2022, 09 pages.
[cited by applicant]
Extended European Search Report issued in European Patent Application No. 20862683.8, dated Sep. 27, 2023, 09 pages.
[cited by applicant]
Extended European Search Report issued in European Patent Application No. 20886462.9, dated Oct. 13, 2023. 9 pages.
[cited by applicant]
Extended European Search Report issued in European Patent Application No. 24182563.7, dated Nov. 8, 2024, 8 pages.
[cited by applicant]
Extended European Search Report issued in European Patent Application No. 19878521.4, dated Oct. 7, 2022, 10 pages.
[cited by applicant]
Fries K.M., et al., “Evidence of Fibroblast Heterogeneity and the Role of Fibroblast Subpopulations in Fibrosis,” Clinical Immunology and Immunopathology, vol. 72, No. 3, 1994, pp. 283-292.
[cited by applicant]
Hematti P., “Mesenchymal Stromal Cells and Fibroblasts: A Case of Mistaken Identity,” Cytotherapy, Mar. 29, 2012, vol. 14, pp. 516-521.
[cited by applicant]
Huang H.I., et al., “Multilineage Differentiation Potential of Fibroblast-like Stromal Cells Derived from Human Skin,” Tissue Engineering Part A, US, May 1, 2010, vol. 16, No. 05, doi:10.1089/ten.tea.2009.0431, pp. 1491…
[cited by applicant]
Huangfu, D. et al. “Induction of Pluripotent Stem Cells from Primary Human Fibroblasts with Only Oct4 and Sox2,” Nature Biotechnology, vol. 26, No. 11. Nov. 2008, pp. 12691275.
[cited by applicant]
International Search Report and Written Opinion for Application No. PCT/US2021/070642, dated Aug. 16, 2021, 10 pages.
[cited by applicant]
International Search Report and Written Opinion for Application No. PCT/US2021/071296, dated Feb. 15, 2022, 15 pages.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2019/030596, mailed Jul. 12, 2019, 9 Pages.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2019/059678, mailed Jan. 27, 2020, 10 Pages.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2019/060397, mailed Feb. 18, 2020, 8 Pages.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2020/060724, mailed Mar. 10, 2021, 9 Pages.
[cited by applicant]
International Search Report and Written Opinion Issued in International Application No. PCT/US2019/059683, Mailed on Jan. 30, 2020, 16 pages.
[cited by applicant]
International Search Report and Written Opinion issued in International Application No. PCT/US2020/049949, mailed Jan. 7, 2021, 12 pages.
[cited by applicant]
Invitation to Pay Additional Fees issued in International Application No. PCT/US2021/071296, dated Dec. 2, 2021, 2 pages.
[cited by applicant]
Kahounova Z., et al., “The Fibroblast Surface Markers FAP, Anti-Fibroblast, and FSP are Expressed by Cells of Epithelial Origin and may be Altered during Epithelial to Mesenchymal Transition,” Cytometry Part A, Apr. 6, …
[cited by applicant]
Kaur J., et al., “Mental Imagery as a Rehabilitative Therapy for Neuropathic Pain in People With Spinal Cord Injury: A Randomized Controlled Trial,” Neurorehabilitation and Neural Repair, vol. 34, No. 11, 2020, pp. 1038…
[cited by applicant]
Lee S.B., et al., “Identification of a Distinct Subpopulation of Fibroblasts From Murine Dermis: CD73() CD105(+) as Potential Marker of Dermal Fibroblast Subset With Multipotency,” Cell Biology International, vol. 40, N…
[cited by applicant]
Lefvre, S. et al., “Synovial Fibroblasts Spread Rheumatoid Arthritis to Unaffected Joints,” Nature Medicine, vol. 15, No. 12, Dec. 2009, pp. 1414-1420.
[cited by applicant]
Li S., et al., “Characteristics of Human Umbilical Cord Mesenchymal Stem Cells during Ex Vivo Expansion,” Molecular Medicine Reports, Jun. 25, 2015, pp. 4320-4325.
[cited by applicant]
Li S., et al., “Conversion of Astrocytes and Fibroblasts into Functional Noradrenergic Neuron,” Cell Reports, Jul. 16, 2019, vol. 28, No. 03, 33 pages.
[cited by applicant]
Lim J.Y., et al., “Therapeutic Effects of Human Umbilical Cord Blood-derived Mesenchymal Stem Cells After Intrathecal Administration by Lumbar Puncture in a Rat Model of Cerebral Ischemia,” Stem Cell Research & Therapy,…
[cited by applicant]
Lin, W., et al., “Mesenchymal Stem Cells Homing to Improve Bone Healing,” Journal of Orthopaedic Translation, vol. 9, 2017, pp. 1927.
[cited by applicant]
Liu S., et al., “Mouse-induced Pluripotent Stem Cells Generated Under Hypoxic Conditions in the Absence of Viral Infection and Oncogenic Factors and Used for Ischemic Stroke Therapy,” Stem Cells and Development, 2014, 2…
[cited by applicant]
Liu X., et al., “The Immunogenicity and Immune Tolerance of Pluripotent Stem Cell Derivatives,” Frontiers in Immunology, 2017, vol. 8, art. 645, 6 pages.
[cited by applicant]
Loupy A., et al., “Immune Response After Pig-to-human Kidney Xenotransplantation: a Multimodal Phenotyping Study,” Lancet, 2023, vol. 402, pp. 1158-1169.
[cited by applicant]
Lv F.J., et al., “Concise Review: The Surface Markers and Identity of Human Mesenchymal Stem Cells,” Stem Cells, May 23, 2014, vol. 32, pp. 1408-1419.
[cited by applicant]
Maleki M., et al., “Comparison of Mesenchymal Stem Cell Markers in Multiple Human Adult Stem Cells,” International Journal of Stem Cells, 2014, vol. 07, No. 02, pp. 118-126.
[cited by applicant]
Maqbool A., et al., “The Substrate-binding protein in bacterial abc transporters: dissecting roles in the evolution of substrate specificity,” Biochemical Society Transactions, 2015, vol. 43(5), pp. 10111017.
[cited by applicant]
Mastri M., et al., “Enhancing the Efficacy of Mesenchymal Stem Cell Therapy,” World Journal of Stem Cells, Apr. 26, 2014, vol. 06, No. 02, ISSN 0005144886, pp. 82-93.
[cited by applicant]
Mcginnis A., et al., “Animal Models of Pain and Anti-inflammatory Treatments,” in Neuroimmune Interactions in Pain, Springer Nature Switzerland AG, 2023, pp. 43-85.
[cited by applicant]
Morita, “A Subpopulation of Fibroblasts Muse Cells, Ameliorate Rat Stroke Model,” The Journal of Physiological Sciences, 65 (Suppl. 1), 2015, 1 page.
[cited by applicant]
Morsing M., et al., “Evidence of Two Distinct Functionally Specialized Fibroblast Lineages in Breast Stroma,” Breast Cancer Research, vol. 18, 2016, pp. 1-11.
[cited by applicant]
Narayan S., et al., “OCT4 and SOX2 Work as Transcriptional Activators in Reprogramming Human Fibroblasts,” Cell Reports, Aug. 15, 2017, 27 pages.
[cited by applicant]
Office Communication issued in Canadian Patent Application No. 3,119,259, dated Feb. 1, 2024, 6 pages.
[cited by applicant]
Official Communication issued in Canadian Patent Application No. 3118760, mailed Dec. 13, 2024, 5 pages.
[cited by applicant]
Oguma Y., et al., “Single-Cell RNA Sequencing Reveals Different Signatures of Mesenchymal Stromal Cell Pluripotent-like and Multi-potent Populations,” Iscience, Nov. 18, 2022, vol. 25, No. 11, 24 pages.
[cited by applicant]
PCT International Search Report and Written Opinion issued in International Application No. PCT/US2021/026752, dated Aug. 12, 2021, 11 Pages.
[cited by applicant]
PCT International Search Report and Written Opinion issued in International Application No. PCT/US/2022/080206, dated Feb. 21, 2023, 12 pages.
[cited by applicant]
Rana N.K., et al., “CoCI2 Simulated Hypoxia Induce Cell Proliferation and Alter the Expression Pattern of Hypoxia Associated Jenes Involved in Angiogenesis and Apoptosis,” Biology Research, vol. 52, No. 1, Article 12, 2…
[cited by applicant]
Rosochowicz M. A., et al., “Conditioned Medium—Is It an Undervalued Lab Waste with the Potential for Osteoarthritis Management?,” Stem Cell Reviews and Reports, 2023, vol. 19, pp. 1185-1213.
[cited by applicant]
Rossi L., et al., “Hematopoietic Stem Cell Characterization and Isolation” Methods in Molecular Biology, 2013, 10 pages.
[cited by applicant]
Sharma K. K., et al., “Neuropathy, Its Profile and Experimental Nerve Injury Neuropathic Pain Models: a Review,” Current Pharmaceutical Design, 2023, vol. 29, pp. 3343-3356.
[cited by applicant]
Sheng Z., et al., “Efficacy of Minocycline in Acute Ischemic Stroke: A Systemic Review and Meta-Analysis of Rodent and Clinical Studies,” Frontiers in Neurology, 2018, 9(1103), 12 pages.
[cited by applicant]
Shi, P. et al. “Therapeutic Effects of Cell Therapy with Neonatal Human Dermal Fibroblasts and Rabbit Dermal Fibroblasts on Disc Degeneration and Inflammation, ” The Spine Journal, vol. 18, 2018, p. 111.
[cited by applicant]
Shinotsuka N., et al., “Fibroblasts: the Neglected Cell Type in Peripheral Sensitisation and Chronic Pain a Review Based on a Systematic Search of the Literature,” BMJ Open Science. 2022;6:e100235. DOI: 10.1136/bmjos-20…
[cited by applicant]
Stappenbeck T.S., et al., “The Role of Stromal Stem Cells in Tissue Regeneration and Wound Repair,” Science, Jun. 26, 2009, vol. 324, No. 5935, doi:10.1126/science. 1172687, ISSN 0036-8075, pp. 1666-1669, Retrieved from…
[cited by applicant]
Sun D, et al., “Basic Fibroblast Growth Factor-enhanced Neurogenesis Contributes to Cognitive Recovery in Rats Following Traumatic Brain Injury,” Experimental Neurology, Mar. 1, 2009, vol. 216, No. 1, pp. 56-65.
[cited by applicant]
Sun J., et al., “Intranasal Delivery of Hypoxia-preconditioned Bone Marrow-derived Mesenchymal Stem Cells Enhanced Regenerative Effects After Intracerebral Hemorrhagic Stroke in Mice,” Experimental Neurology, Oct. 2015,…
[cited by applicant]
Sun X., et al., “CXCL12/CXCR4/CXCR7 Chemokine Axis and Cancer Progression,” Cancer and Metastasis Reviews, Dec. 2010, vol. 29, No. 04, pp. 709-722.
[cited by applicant]
Tang C, et al., “FGF2 Attenuates Neural Cell Death via Suppressing Autophagy After Rat Mild Traumatic Brain Injury,” Stem Cells International, 2017, vol. 2017, Article ID 2923182, 11 pages.
[cited by applicant]
Tassew N.G., et al., “Exosomes Mediate Mobilization of Autocrine Wnt10b to Promote Axonal Regeneration in the Injured CNS,” Cell Reports, 2017, 20(1), pp. 99-111.
[cited by applicant]
Teicher B.A., et al., “CXCL12 (SDF-1)/CXCR4 Pathway in Cancer,” Clinical Cancer Research, Molecular Pathways, Jun. 1, 2010, vol. 16, No. 11, pp. 2927-2931.
[cited by applicant]
Thau-Zuchman O, et al., “Combination of Vascular Endothelial and Fibroblast Growth Factor 2 for Induction of Neurogenesis and Angiogenesis After Traumatic Brain Injury,” May 2012), Journal of Molecular Neuroscience, vol…
[cited by applicant]
Uchida H., et al., “Transplantation of Unique Subpopulation of Fibroblasts, Muse Cells, Ameliorates Experimental Stroke Possibly via Robust Neuronal Differentiation”, Stem Cells, Sep. 28, 2015, vol. 34, No. 01, pp. 160-…
[cited by applicant]
Vadala G., et al., “Stem Cells Sources for Intervertebral Disc Regeneration,” World Journal of Stem Cells, May 26, 2016, vol. 08, No. 05, pp. 185-201.
[cited by applicant]
Wang K.K., et al., “An Update on Diagnostic and Prognostic Biomarkers from Traumatic Brain Injury,” Expert Review of Molecular Diagnostics, 2019, 31 pages.
[cited by applicant]
Wang X., et al., “Hypoxia Precondition Promotes Adipose-Derived Mesenchymal Stem Cells Based Repair of Diabetic Erectile Dysfunction via Augmenting Angiogenesis and Neuroprotection,” PLoS One, vol. 10, No. 3, Article e0…
[cited by applicant]
Wang Y., et al., “Roles of Chemokine CXCL12 and its Receptors in Ischemic Stroke,” Current Drug Targets, Feb. 2012, vol. 13, No. 02, pp. 166-172.
[cited by applicant]
Wernig M., et al., “Neurons Derived from Reprogrammed Fibroblasts Functionally Integrate into the Fetal Brain and Improve Symptoms of Rats with Parkinson's Disease,” Proceedings of the National Academy of Science, Apr. …
[cited by applicant]
Weston N.M., et al., “The Potential of Stem Cells in Treatment of Traumatic Brain Injury,” Current Neurology and Neuroscience Reports, Jan. 25, 2018, 17 pages.
[cited by applicant]
Wikipedia, “Muscle,” Wikipedia.com, Mar. 30, 2018, 2 pages.
[cited by applicant]
Wong T., et al., “The Role of Fibroblasts in Tissue Engineering and Regeneration,” British Journal of Dermatology, Jun. 1, 2007, vol. 156, No. 06, pp. 1149-1155.
[cited by applicant]
Yamashita et al., “Non-Tumorigenic Pluripotent Reparative Muse Cells Provide a New Therapeutic Approach for Neurologic Diseases,” Cells, 10:961, 2021, 21 Pages.
[cited by applicant]
Yoder M.C., “Endothelial Stem and Progenitor Cells,” (Stem Cells): (2017 Grover Conference Series), Pulmonary Circulation, Nov. 3, 2017, 9 pages.
[cited by applicant]
Zeddou M., et al., “Umbilical Cord Fibroblasts: Could They Be Considered As Mesenchymal Stem Cells?,” World J Stem Cells (World Journal of Stem Cells, 2014, vol. 6, No. 3, pp. 367-370.
[cited by applicant]
Zhao B., et al., “Hypoxia drives the transition of human dermal fibroblasts to a myofibroblast- like phenotype via the TGF-b1/Smad3 pathway,” International Journal of Molecular Medicine, vol. 39, 2017, pp. 153-159.
[cited by applicant]